HLA-DRB6 antigen

Also Known As:

HLA DRB6; HLA-DRB6; HLA-DRB6*01:01 antigen; HLA-DRB6*02:01 antigen; HLA-DRB6*02:02 antigen

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2
  - Membrane Proteins: 10078
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2
Biological Factors: 2472
- Antigens: 143924
  - Surface Antigens: 5813
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2
  - Isoantigens: 1221
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR beta-Chains: 64
        HLA-DRB6 antigen: 2

Experts

1.	Chen, Peixin: 1 article (01/2021)
2.	Dai, Jiawei: 1 article (01/2021)
3.	Guo, Haoyue: 1 article (01/2021)
4.	He, Kan: 1 article (01/2021)
5.	He, Yayi: 1 article (01/2021)
6.	Jiang, Minlin: 1 article (01/2021)
7.	Lu, Hui: 1 article (01/2021)
8.	Wang, Hao: 1 article (01/2021)
9.	Zhao, Wencheng: 1 article (01/2021)
10.	Zhou, Caicun: 1 article (01/2021)

Related Diseases

1.	Nervous System Diseases (Neurological Disorders) 05/05/2016 - "Targeted bis-seq confirmed hap-ASM in 12/13 loci tested, including CCDC155, CD69, FRMD1, IRF1, KBTBD11, and S100A(∗)-ILF2, associated with immune phenotypes, MYT1L, PTPRN2, CMTM8 and CELF2, associated with neurological disorders, NGFR and HLA-DRB6, associated with both immunological and brain disorders, and ZFP57, a trans-acting regulator of genomic imprinting. "
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/01/2021 - "DDR-deficient types had lower expressions of STING1 (p = 0.01), CD28 (p = 0.020), HLA-DRB6 (p = 0.014) in adenocarcinoma, lower TNFRSF4 (p = 0.017), and TGFB1 expressions (p = 0.033) in squamous carcinoma, and higher CD40 (p = 0.012) and TNFRSF14 expressions (p = 0.022) in SCLC. "
3.	Brain Diseases (Brain Disorder) 05/05/2016 - "Targeted bis-seq confirmed hap-ASM in 12/13 loci tested, including CCDC155, CD69, FRMD1, IRF1, KBTBD11, and S100A(∗)-ILF2, associated with immune phenotypes, MYT1L, PTPRN2, CMTM8 and CELF2, associated with neurological disorders, NGFR and HLA-DRB6, associated with both immunological and brain disorders, and ZFP57, a trans-acting regulator of genomic imprinting. "
4.	Adenocarcinoma 01/01/2021 - "DDR-deficient types had lower expressions of STING1 (p = 0.01), CD28 (p = 0.020), HLA-DRB6 (p = 0.014) in adenocarcinoma, lower TNFRSF4 (p = 0.017), and TGFB1 expressions (p = 0.033) in squamous carcinoma, and higher CD40 (p = 0.012) and TNFRSF14 expressions (p = 0.022) in SCLC. "